Products

SASPject™ can potentially be targeted at any bacteria but initial products in development are focused on three groups of multi-drug resistant bacteria, or “superbugs”.

SASPject™ PT1.2 is aimed at Staphylococcus aureus, including MRSA. MRSA infections were first detected in the late 1990s but are now a global problem in hospitals, control of which is vital to many national health systems. Thousands of fatalities have been recorded as a direct result of MRSA infection. SASPject™ PT1.2 will be used for the intra-nasal decolonisation of the bacteria. A Phase I clinical trial has been successfully completed and Phase II trials will commence in Q3 2010.

SASPject™ PT3.1I is being developed against Pseudomonas aeruginosa. This bacteria commonly causes respiratory infections and is naturally resistant to many antibiotics. P. aeruginosa is a particular problem in cystic fibrosis sufferers where it colonises the lungs. In these patients, conventional antibiotics can only rarely clear the lungs of this infection. SASPject™ PT3.1I will be administered by inhalation.

SASPject™ PT3.XS is being developed for systemic (intravenous) use against antibiotic resistant Gram negative bacteria including E. coli, K. pneumoniae and P. aeruginosa. These bacteria can cause serious infections, and isolates which are resistant to almost all conventional antibiotics are now starting to spread around the globe and can result in very poor treatment outcomes.

SASPject™ PT4.X is being developed from SASPject™ PT1.2 for use against systemic staphylococcal infections. It will be administered by injection with potential to act as a stand-alone therapy or as an add-on to existing broad-spectrum antibiotics.